EUVIMEDEUVIMED entdecken
Crossref

Disturbed flow induced targeting of nanomedicine to endothelial cells for effective atherosclerosis therapy

Lin Fu iD, Meixi Quan, Ziyan Zhao, Runpu Ma, Yuhan Jiang, Wenhui Zhang, Yuting Li, Jia Zhang, Huan Meng, Ding Ai, Yi Zhu, Kangyin Chen iD und 2 weitere

Cardiovascular Research · 22.05.2026 · 122 (7) · 858-873

DOI: 10.1093/cvr/cvag062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 13.05.2026. Verfasst von Lin Fu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospi…. Hauptthemen laut MEDLINE: Endothelial Cells, Nanoparticles, Atherosclerosis, Nanomedicine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Tianjin Municipal Health Science and Technology Project, Tianjin Key Medical Discipline Construction.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Atherosclerotic plaques preferentially form at the vascular bifurcations and inner curvature of the aortic arch, where oscillatory shear stress (OSS) induces endothelial cell (EC) inflammation, which is a key driver of disease progression. Given that endothelial cell inflammation is the primary initiating factor, using nanoparticles for site-specific drug delivery may facilitate precise therapeutic intervention. We aimed to determine whether use of a STRN3-derived Hippo-activating peptide (SHAP) laden silicasome (SLS) nanocarrier (SHAP-SLS) possessed the ability to inhibit EC activation and protect against atherosclerosis induced by disturbed flow. Methods and results In a mouse model of partial left carotid artery ligation, we identified the ability of SLS nanocarrier, i.e. a lipid bilayer-coated mesoporous silica nanoparticle (MSNP), that specifically targeted inflammatory regions. We loaded the mammalian sterile 20-like kinase 1 (MST1) activator SHAP into the MSNP core of SLS. SHAP-SLS significantly inhibited EC inflammation and atherosclerosis progression by upregulating the phosphorylation of MST1. To further investigate the mechanism by which SHAP-SLS inhibits endothelial activation, we immunoprecipitated biotin-labelled SLS and performed proteomic analysis. We found that the endocytic adaptor proteins NUMB isoforms 1 and 2 bind to membrane-associated SLS and mediate the internalization of SHAP-SLS into endothelial cells.

Conclusion

SHAP-SLS represents a promising nanomedicine approach for inhibiting endothelial inflammation and limiting atherosclerosis progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endothelial CellsNanoparticlesAtherosclerosisNanomedicineSilicon DioxideCarotid Artery DiseasesDrug CarriersAnimalsProtein Serine-Threonine KinasesHumansDisease Models, AnimalMice, Inbred C57BLHippo KinasesMalePhosphorylationProto-Oncogene ProteinsSignal TransductionPlaque, Atherosclerotic

Stichwörter der Autor:innen

AtherosclerosisEndothelial inflammationMammalian sterile 20-like kinase 1NUMBSTRN3-derived Hippo-activating peptideSilicasome

Substanzen

Protein Serine-Threonine KinasesSilicon DioxideHippo KinasesDrug CarriersProto-Oncogene Proteins

Autor:innen und Institutionen

  • Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi Distri…
  • Department of Physiology and Pathophysiology, Tianjin Medical University, 22 Qixiangtai Road, Tianjin 300070, China.
  • Hangzhou Institute of Medicine, Chinese Academy of Sciences, The Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310018, C…
  • CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology, Beijing 100190, China.

ORCID-Profile: Lin Fu, Kangyin Chen, Tong Liu

Förderung

  • National Natural Science Foundation of China
  • Tianjin Municipal Health Science and Technology Project
  • Tianjin Key Medical Discipline Construction
  • Natural Science Foundation of Tianjin
  • Hangzhou Institute of Medicine
  • Chinese Academy of Sciences

Zitieren

APA

Fu, L., Quan, M., Zhao, Z., Ma, R., Jiang, Y., Zhang, W., Li, Y., Zhang, J., Meng, H., Ai, D., Zhu, Y., Chen, K., Liu, X., & Liu, T. (2026). Disturbed flow induced targeting of nanomedicine to endothelial cells for effective atherosclerosis therapy. Cardiovascular Research, 122(7), 858-873. https://doi.org/10.1093/cvr/cvag062

Vancouver

Fu L, Quan M, Zhao Z, Ma R, Jiang Y, Zhang W, et al. Disturbed flow induced targeting of nanomedicine to endothelial cells for effective atherosclerosis therapy. Cardiovascular Research. 2026;122(7):858-873. doi:10.1093/cvr/cvag062

BibTeX
@article{Fu2026,
  author = {Fu, Lin and Quan, Meixi and Zhao, Ziyan and Ma, Runpu and Jiang, Yuhan and Zhang, Wenhui and Li, Yuting and Zhang, Jia and Meng, Huan and Ai, Ding and Zhu, Yi and Chen, Kangyin and Liu, Xiangsheng and Liu, Tong},
  title = {Disturbed flow induced targeting of nanomedicine to endothelial cells for effective atherosclerosis therapy},
  journal = {Cardiovascular Research},
  year = {2026},
  volume = {122},
  number = {7},
  pages = {858--873},
  doi = {10.1093/cvr/cvag062}
}
Kostenlos starten →